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Abstract Porcine circovirus type 2 (PCV2) is the primary
causative agent of porcine circovirus-associated diseases in
pigs. The sole structural capsid protein of PCV2, Cap, consists
of major antigenic domains, but little is known about the
assembly of capsid particles. The purpose of this study is to
produce a large amount of Cap protein using Escherichia coli
expression system for further studying the essential sequences
contributing to formation of particles. By using codon opti-
mization of rare arginine codons near the 5′-end of the cap
gene for E. coli, a full-length Cap without any fusion tag
recombinant protein (Cap1-233) was expressed and pro-
ceeded to form virus-like particles (VLPs) in normal Cap
appearance that resembled the authentic PCV2 capsid. The
N-terminal deletion mutant (Cap51-233) deleted the nuclear
localization signal (NLS) domain, while the internal deletion
mutant (CapΔ51-103) deleted a likely dimerization domain
that failed to form VLPs. The unique Cys108 substitution
mutant (CapC/S) exhibited most irregular aggregates, and
only few VLPs were formed. These results suggest that the
N-terminal region within the residues 1 to 103 possessing the
NLS and dimerization domains are essential for self-assembly
of stable Cap VLPs, and the unique Cys108 plays an impor-
tant role in the integrity of VLPs. The immunogenicity of
PCV2 VLPs was further evaluated by immunization of pigs
followed by challenge infection. The Cap1-233-immunized
pigs demonstrated specific antibody immune responses and are
prevented from PCV2 challenge, thus implying its potential use
for a VLP-based PCV2 vaccine.
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Introduction
Porcine circovirus (PCV) is a member of the family
Circoviridae consisting of a circular single-stranded DNA ge-
nome. The virions are icosahedral, nonenveloped, and 20.5 nm
in diameter (Crowther et al. 2003). PCV type 1 is nonpatho-
genic in swine and was first described in 1974 as a persistent
contaminant of a porcine kidney PK-15 cell line (ATCC-
CCL33, Tischer et al. 1986; Allen et al. 1995). In contrast, type
2 PCV (PCV2) is closely associated with a newly emerged
disease called postweaning multisystemic wasting syndrome
(PMWS) in growing pigs now known as porcine circovirus-
associated diseases (Allan and Ellis 2000). The characteristic
symptoms of the syndrome include severe progressive weight
loss, dyspnea, tachypnea, anemia, diarrhea, and lymphadenop-
athy in pigs of 5–15 weeks of age (Allan and Ellis 2000; Ellis et
al. 2004; Chae 2005). PMWS is endemic in the majority of the
swine-producing countries, causing a severe economic impact
on the swine industry worldwide.
The PCV2 genome has two major open reading frames
(ORFs). They are ORF1, the rep gene, which encodes the
Rep proteins responsible for virus replication and ORF2, the
cap gene, which encodes the immunogenic capsid (Cap)
protein (Mankertz et al. 1998; Truong et al. 2001). A recent
P.-C. Wu :W.-L. Lin : J.-N. Chi : C. Huang (*)
Graduate Institute of Microbiology and Public Health, College
of Veterinary Medicine, National Chung Hsing University,
250 Kuo Kuang Road,
Taichung 40227 Taiwan, Republic of China
e-mail: cjhuang@dragon.nchu.edu.tw
C.-M. Wu :M.-S. Chien (*)
Graduate Institute of Veterinary Pathobiology, College of
Veterinary Medicine, National Chung Hsing University,
250 Kuo Kuang Road,
Taichung 40227 Taiwan, Republic of China
e-mail: mschien@dragon.nchu.edu.tw
Appl Microbiol Biotechnol (2012) 95:1501–1507
DOI 10.1007/s00253-012-4015-2
report showed that a nonstructural protein encoded by ORF3
could induce apoptosis in the PCV2-infected cultured cells
(Liu et al. 2005). The only structural protein of viral capsid,
Cap, has become the major target for developing PCV2
vaccines and serological diagnostic reagents. Several re-
combinant Cap proteins expressed by the recombinant bacu-
lovirus expression system have been used as ELISA
antigens and further as a subunit vaccine (Nawagitgul et
al. 2000; Beach and Meng 2011). However, the production
of recombinant proteins in the eukaryotic expression sys-
tems is more laborious and expensive. Since the N-terminal
41 amino acid (a.a.) residues of the PCV2 Cap protein
possess a nuclear localization signal (NLS) containing the
high incidence of arginine residues and rare codons for E.
coli that was disadvantageous for full-length Cap expression
(Liu et al. 2001; Zhou et al. 2005). Deletion of NLS
(Trundova and Celer 2007) or fusion to a tag such as
glutathione-S-transferase (Zhou et al. 2005) has been
employed to improve the expression efficiency and stability
of expressed protein in E. coli. The crystal structure of an N-
terminally truncated PCV2 virus-like particle (VLP) at 2.3-
Å resolution has been determined (Khayat et al. 2011). A
full-length Cap has recently been demonstrated to express in
E. coli by adapting codon usage and supplementing the host
with rare tRNAs but has failed to self-assemble into VLPs
(Marcekova et al. 2009).
The N-terminus of the PCV2 Cap contains residues rich in
basic amino acids. Thus, it may be involved in the formation
of the interior surface of the virion and interact with the
negative charges of genomic DNA during virus assembly
(Lekcharoensuk et al. 2004; Meehan et al. 1998). Studies on
the hepatitis B virus (HBV) capsid particle assembly reveal
that capsid proteins assemble into dimmers which provide the
precursor, or assembly units for capsid formation (Zhou and
Standring 1992a), and the Cys residues of capsid protein are
not essential for particle assembly but can influence their
stability (Zhou and Standring 1992b). Very little is known
about the assembly of the PCV2 capsid particles, since insuf-
ficient quantities of purified virus are available for detailed
studies. The purpose of this study is to produce a large amount
of full-length Cap recombinant protein resembling the authen-
tic native viral Cap using E. coli expression system, and
further to study the essential sequences for particle assembly
and immunogenicity of the PCV2 VLPs.
Materials and methods
Cloning of PCV2 cap gene by PCR and construction
of recombinant expression plasmids
PCV2 genomic DNAwas extracted with a commercial DNA
extraction kit (QIAamp Tissue kit, QIAGEN) from 20 mg of
frozen lymph nodes that was collected from a severe
PMWS-affected piglet in a commercial farm in central
Taiwan. The PCR primer pairs were designed according to
the PCV2 Taiwan strain sequence (GenBank accession no.
AY885225) and used for amplification of the defined coding
region of PCV2 Cap (Table 1). The PCR reaction was
carried out as described previously (Wu et al. 2008). The
full length of the cap gene which was amplified with the
primer pair mCapF1/2 and CapR233 was digested with
restriction enzymes BglII/XhoI followed by cloning into
the expression vector ΔpFlag which is derived from
pFlag-1 (IBI) by deleting the franking region of FLAG tag
(Fig. 1b) to generate the recombinant plasmid ΔpFlagCap1-
233. The cap gene lacking the NLS region, which was
amplified with the primer pair Cap51/BglII and CapR233,
was digested with restriction enzymes BglII/XhoI followed
by cloning into the expression vectorΔpFlag to generate the
recombinant plasmid ΔpFlagCap51-233. The DNA frag-
ment encoding the a.a. 1–50 of Cap was amplified with
the primer pair mCapF1/2 and CapR50-2, followed by clon-
ing to the ΔpFlagCap1-233 and replacing the fragment
encoding the a.a. 1–103 of Cap with BglII/EcoRI digestion
to generate the recombinant plasmid ΔpFlagCapΔ51-103.
The DNA fragment encoding the a.a. 102–233 of Cap with
the substitution from cysteine to serine at a.a. 108 was
amplified with the primer pair CapC/S and CapR233, fol-
lowed by cloning to the ΔpFlagCap1-233 and replacing the
fragment encoding the a.a. 102–233 of Cap with EcoRI/
XhoI digestion to generate the recombinant plasmid
ΔpFlagCapC/S (Fig. 1a). All the recombinant plasmids
were sequenced to confirm the accuracy of the open reading
frame of cap coding sequences.
Expression of Cap protein in E. coli and purification
of VLPs
Recombinant expression plasmids were transformed respec-
tively into E. coli BL21-codon Plus (DE3)-RIL competent
cells (Stratagene) according to the manufacturer’s manual.
A single colony of transformant was grown in Luria–Bertani
medium containing 50 μg/ml ampicillin at 37 °C until the
OD600 reached 0.6. Then isopropyl β-D-thiogalactopyrano-
side was added to a final concentration of 1 mM. The culture
was incubated for an additional 4 h at 30 °C. The cells were
harvested by centrifugation at 6,000×g for 10 min at 4 °C
and resuspended in Tris buffer [50 mMTris (pH 7.2), 150 mM
NaCl, 0.2 % Triton-X 100, 1 mM protease inhibitor, 5 %
glycerol]. Cells were broken by sonication followed by cen-
trifugation at 15,000×g for 10 min at 4 °C, and proteins were
analyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and Western blotting analysis. The
supernatant was further transferred to a centrifuge tube con-
taining equal volume of 40% sucrose cushion and centrifuged
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at 210,000×g for 6 h at 4 °C for purification of VLPs. The
pellet was resuspended with 0.5 ml of Tris buffer and exam-
ined by transmission electron microscope (TEM).
Western blotting analysis
Expressed proteins were resuspended in equal volumes of 2×
SDS-PAGE sample buffer [125 mM Tris–Cl (pH 6.8), 20 %
glycerol, 4 % SDS, 0.25 % bromophenol blue] in the presence
or absence of 10 % β-mercaptoethanol. Proteins were
separated by 12 % SDS-PAGE and then transferred by electro-
blotting onto PolyScreen PVDF transfer membrane (NEN)
using semidry transfer cell (Bio-Rad) according to the manu-
facturer’s manual. The membrane was then treated sequentially
with blocking solution [phosphate-buffered saline (PBS) con-
taining 5 % skim milk], with appropriate dilution of mouse
antiserum specific to Cap, and with anti-mouse IgG goat anti-
body conjugated to peroxidase (Zymed). Finally, the mem-
brane was soaked in a chromogen/substrate solution (TMB
single solution; Zymed) for color development.
Table 1 Sequences of oligonucleotides used for cloning the defined coding region of PCV2 Cap protein
a The specific sequence on the PCV2 ORF2 gene are underlined, and the nucleotide numbers (GenBank accession no. AY885225) are indicated.
The sequences recognized by the restriction enzyme are boxed. The mutants are indicated by gray boxes
Fig. 1 Construction of recombinant expression plasmids expressing
different Cap proteins. a Schematic diagram of the expressed coding
regions of PCV2 Cap recombinant subunits. Bars represent expressed
coding sequences, and the amino acid residue numbers at both termini
are indicated. b The cloning plasmid ΔpFlag with the flanking region
of FLAG tag deleted
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Transmission electron microscope
Purified VLPs were adsorbed onto a copper grid for 3 min at
room temperature. The grids were dried gently using filter
paper and stained with saturated aqueous uranyl acetate for
40 s. The excess liquid was removed with filter, and the
samples were examined under a TEM (JEOL JEM1400).
Immunization of pigs and challenge infection
Five 6-week-old SPF piglets were randomly allotted to the
Cap (n03) and control (n02) groups. Each piglet was im-
munized intramuscularly into the neck region with 200 μg
Cap VLP (Cap group) or normal saline (control group) in a
1:1 water-in-oil-in-water emulsion with the adjuvant
ISA201 (SEPPIC) twice at a 2-week interval. The pigs were
challenged intranasally and intramuscularly via the neck
with 1 ml of 1×105 TCID50 PCV2 at 2 weeks after booster
immunization. Pigs were checked daily for clinical signs,
and the body weight was measured weekly. At 4 weeks
post-challenge (p.c.) infection, the surviving animals were
euthanized according to the guidelines of the Institutional
Animal Care and Use Committee of National Chung Hsing
University, and a necropsy was performed.
Indirect enzyme-linked immunosorbent assay
Serum blood samples were tested for PCV2 Cap-specific
antibodies with an indirect enzyme-linked immunosorbent
assay (ELISA). ELISA plates (Nunc) were coated at 4 °C
overnight with 50 μl volume of 10 μg/ml purified Cap1-233
in coating buffer (carbonate buffer, pH 9.6). Each well was
then thoroughly washed with PBS containing 0.05 %
Tween-20 (PBST) and was added 50 μl volume of tested
swine (1:100 diluted) serum in blocking buffer (PBS con-
taining 1 % bovine serum albumin) containing 5 % E. coli
lysate and incubated at 37 °C for 1 h. Subsequently, the plate
was washed with PBST thoroughly, and each well was
added 50 μl volume of 2,000-fold dilution of goat anti-
swine IgG conjugated to peroxidase (Zymed) in blocking
buffer at 37 °C for 45 min. The plate was washed with PBST
three times followed by washing with PBS twice. Fifty
microliters of freshly prepared chromogen/substrate solution
(ABTS single solution, Zymed) was added into each well,
and the plate was incubated at room temperature for 15 min
in the dark. Finally, the reaction was stopped by adding an
equal volume of stop solution (2 % SDS). Optical density
(OD) of each well was read at 405 nm using a microplate
reader (MRXII, Dynex). Each sample was analyzed in du-
plicate, and the OD405 of duplicates was averaged. The
mean OD405 of SPF swine sera and an anti-PCV2 polyclone
serum (VMRD) were used as negative and positive controls,
respectively, to optimize the assays. Mean sample/positive
(S/P) ratio of duplicate of each test was calculated.
Results
Expression of Cap protein variants in E. coli
In order to study the capsid assembly, variant Cap recombi-
nant proteins without any fusion tag were expressed in E.
coli. The defined coding regions of cap gene were amplified
by PCR using carefully designed primer pairs (Table 1) and
cloned into the expression vector ΔpFlag (Fig. 1b) to con-
struct the recombinant plasmids including ΔpFlagCap1-
233, ΔpFlagCap51-233, ΔpFlagCapΔ51-103, and
ΔpFlagCapC/S (Fig. 1a). Four out of seven arginine codons
near the utmost 5′ end of cap gene were optimized for
efficient codon usage in E. coli. Those recombinant plas-
mids transformed respectively into E. coli BL21-codon plus
(DE3)-RIL competent cells which contain extra copies of
argU, ileY, and leuW genes for rare tRNAs, and the
expressed proteins were characterized by Western blotting
analysis. The full-length Cap protein which consisted 233
a.a. residues with the molecular weights of 25.7 kDa in size
was expressed and designated Cap1-233. Two deletion
mutants including an N-terminal deletion mutant (Cap51-
233) lacking the NLS domain located at a.a. 1–50, and an
internal deletion mutant (CapΔ51-103) lacking the portion
of a.a. 51–103 were also successfully expressed with the
estimated molecular weights of 20.1 and 19.9 kDa, respec-
tively. Another full-length mutant designated CapC/S was
constructed by substituting the unique cysteine (a.a. 108) of
Cap to serine. All of the Cap recombinant proteins could be
specifically recognized by the antiserum against PCV2 Cap,
while except for CapC/S, all other three including Cap1-233,
Cap51-233, and CapΔ51-103 were able to form homodimer
in the absence of β-mercaptoethanol (Fig. 2).
Particles formed by the full length of Cap protein
The soluble expressed proteins were further purified by
ultracentrifugation to detect whether the Cap protein is able
to self-assemble into VLPs. TEM images of each purified
protein revealed that only the full-length Cap protein (Cap1-
233) could assemble into VLPs with diameter ranging from
15 to 20 nm (Fig. 3a). The full-length cysteine substitution
mutant (CapC/S) exhibited most irregular aggregates, and
only few VLPs were formed (Fig. 3d).
Immunization of pigs and challenge infection
To evaluate the immunogenicity of Cap VLPs, three 6-
week-old SPF piglets (nos. 1–3) were immunized
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intramuscularly with 200 μg Cap1-233 twice at a 2-week
interval, while two control piglets (nos. 4–5) were immu-
nized with normal saline. All Cap-immunized pigs serocon-
verted to Cap-specific antibody after booster immunization
as determined by an indirect ELISA, while no antibody
detected in the control pigs (Fig. 4a). The specificity of
immune serum was further confirmed by indirect immuno-
fluorescence with the Porcine Circovirus FA substrate slides
(VMRD, USA) according to the manufacturer’s manual.
After challenge infection, the control pigs exhibited growth
stagnation and diarrhea, and had to be euthanized at 14 days
due to severe clinical symptoms. In contrast, the Cap-
immunized pigs grew healthily (Fig. 4b) without any clinical
symptom, and postmortem analysis at 4 weeks p.c. revealed
no evidence of PCV2 infection.
Discussion
PCV2 is a recognized essential infectious agent behind the
development of PMWS, which is currently regarded as an
important infectious swine viral disease, that results in a
serious economic impact on the pig industry worldwide.
The PCV2 Cap protein consists of major antigenic domains,
suggesting its diagnostic and subunit vaccine potentials
(Nawagitgul et al. 2002; Liu et al. 2004). Currently, com-
mercially available PCV2 subunit vaccines have been de-
veloped using the baculovirus expression system. The
recombinant Cap expressed in insect cells could assemble
to form VLPs (Nawagitgul et al. 2002). However, the ex-
pression level is limited, and the cost of cell culture and time
consumption in purification of expressed products are major
concerns. In contrast, the E. coli expression systems have
been utilized successfully for high-level expression of many
heterologous proteins because of its relative simplicity, low
cost, and fast high-density cultivation (Yin et al. 2010). The
N-terminal NLS domain of the Cap protein is rich in argi-
nine residues and contains several rare codons for E. coli
that hampers a foreign gene expression (Liu et al. 2001;
Zhou et al. 2005). Thus, using codon optimization and an
alternative E. coli host strain which contains extra copies of
genes for rare tRNAs can circumvent the difficulty of high-
level expression of full-length Cap. The full-length Cap1-
233 without any fusion tag was successfully expressed and
Fig. 2 a, b Characterization of recombinant Cap proteins by Western
blotting analysis. Purified different Cap proteins were separated by
12 % SDS-PAGE in the presence (plus sign) or absence (minus sign)
of β-mercaptoethanol followed by Western blotting analysis with
mouse immune serum specific to PCV2 Cap. Lanes 1–5 are purified
Cap1-233, Cap51-233, CapΔ51-103, CapC/S, and E. coli competent
cell lysate, respectively. The expected Cap protein is indicated by an
arrow and the dimmer form of Cap is indicated by an asterisk
Fig. 3 TEM images of Cap protein VLPs of PCV2. Purified Cap1-233 (a), Cap51-233 (b), CapΔ51-103 (c), CapC/S (d), and E. coli competent
cell lysate (e) were negatively stained and observed by TEM. Scale bar 50 nm
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proceeded to form VLPs. The small ubiquitin-like modifiers
(SUMO) fusion protein expression system has recently been
employed successfully to improve highly soluble full-length
Cap-tag fusion protein expressed in E. coli, and the
expressed Cap has the ability to self-assemble into VLPs
after the protease cleavage of the SUMO fusion motif (Yin
et al. 2010). Nevertheless, the tag motif may interfere with
the protein conformation and antigenicity, and the cleavage
and purification processes may be cumbersome and costly.
The PCV2 Cap contains sole cysteine residue at a.a. 108
(Cys108). In order to examine the role played by the Cys108
in the assembly of either dimmers or capsids, a Cys-minus
mutant (CapC/S) was constructed. Those expressed proteins
retaining the Cys108 such as Cap1-233, Cap51-233, and
CapΔ51-103 could form homodimer in the absence of β-
mercaptoethanol, while the full-length Cys108 substitution
mutant CapC/S abolished this activity. This result suggests
that the unique cysteine is responsible for dimmer formation
of Cap via formation of a disulfide bond. In addition, in our
previous study on the development of Cap subunit-based
indirect ELISAs (Wu et al. 2008), the Cap subunit B
representing the a.a. 51–100 exhibited both monomer and
dimmer forms in the reducing condition (data not shown),
leading to our speculation that this region might be related to
a dimerization domain. The internal deletion mutant
CapΔ51-103 did not show that the formation of VLPs
seems to confirm our hypothesis. Only the full-length
Cap1-233 demonstrated self-assembly into VLPs, suggest-
ing that both regions in the N-terminal NLS domain and
internal a.a. 51–103, a likely dimerization domain, are es-
sential for capsid assembly. Indispensable sequences or
motifs conferring VLPs formation are currently under study.
Further, the Cys108 substitution mutant CapC/S exhibited
most irregular aggregates but only few VLPs were formed,
indicating that the Cys108 is dispensable for capsid assembly
but formation of the disulfide bond is important for the integrity
of the Cap VLPs.
VLPs mimic the structure of authentic virus particles and
they are safe and very efficient at stimulating both cellular and
humoral immune responses (Noad andRoy 2003; Antonis et al.
2006). Several VLPs from many viruses have been developed
as vaccine candidates including two commercialized VLP-
based vaccines that succeed in protecting humans from HBV
and human papillomavirus infection (Grgacic and Anderson
2006; Ludwig andWagner 2007). The immunogenicity of Cap
VLPs was confirmed by the Cap1-233-immunized pigs that
elicited specific antibody responses against Cap and offer
prevention from PCV2 infection. A large-scale field trial is
undertaken by comparing the growth performance between
Cap1-233-vaccinated and unimmunized pigs.
Fig. 4 Time course of ELISA
antibody development (a) and
body weight (b) of the VLP-
immunized pigs after vaccina-
tion and challenge
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In conclusion, a full-length authentic Cap protein of
PCV2 has been successfully expressed using a modified E.
coli expression system, and the expressed Cap was able to
self-assemble into VLPs. Further characterizing variant Cap
recombinant proteins reveals that the region in the N-terminal
103 residues containing the NLS and the likely dimerization
domains are required for self-assembly of stable VLPs, and
the sole Cys108 plays an important role in the integrity of
VLPs. The PCV2 VLP-immunized pigs could elicit specific
antibody responses and were prevented from PCV2 challenge,
thus suggesting its potential as an alternative PCV2 subunit
vaccine candidate with advantages of easy preparation and
low cost.
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